Drug Trial Radar · NCT07318675
A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.
Last checked: Nov 20, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 25, 2025
Primary completion
Mar 2026
Study completion Mar 2026
Sponsor
- Lead sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase Ib study to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HW211026 ointment after single or multiple topical administrations in patients with actinic keratosis.
Conditions
- Actinic Keratosis (AK)
Interventions
HW211026Drug
Dose 1 and Dose 2
PlaceboDrug
Dose 1 and Dose 2
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number and severity of treatment emergent adverse events (TEAEs)Time frame: up to 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Skin Disease Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.